Literature DB >> 7981484

Drug-induced parkinsonism in the aged. Recognition and prevention.

O S Gershanik1.   

Abstract

Drug-induced Parkinsonism is a frequent adverse effect of numerous drugs interfering with dopamine function at the basal ganglionic level. It accounts for 4% of all patients with Parkinsonism seen in neurology clinics. Pharmacological agents implicated in the production of this disorder have a wide range of applications in medicine, beyond the treatment of psychiatric illnesses. Antipsychotics, substituted benzamides and calcium channel blockers are the drugs most commonly involved. The aged population is at an increased risk of drug-induced Parkinsonism due to intrinsic factors and because they often receive multiple drugs, including those from self-medication. Lack of knowledge in the medical profession of the potential hazards involved in the use of certain drugs plays a contributory role in the development of drug-induced Parkinsonism. Physicians should be always alert in order to detect, as early as possible, the presence of extrapyramidal symptoms in patients exposed to medications with antidopaminergic properties. Whenever possible, withdrawal of the medication will help resolve symptoms; complete remission takes place within 6 to 18 months in the majority of patients. The use of anti-Parkinsonian drugs is only advisable if the symptomatology is disabling. The best available treatment is prevention.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7981484     DOI: 10.2165/00002512-199405020-00006

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  20 in total

1.  [Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)].

Authors:  J DELAY; P DENIKER; J M HARL
Journal:  Ann Med Psychol (Paris)       Date:  1952-06       Impact factor: 0.380

2.  Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors.

Authors:  J K Chivers; W Gommeren; J E Leysen; P Jenner; C D Marsden
Journal:  J Pharm Pharmacol       Date:  1988-06       Impact factor: 3.765

Review 3.  Differential diagnosis of Parkinson's disease and the parkinsonism plus syndromes.

Authors:  M Stacy; J Jankovic
Journal:  Neurol Clin       Date:  1992-05       Impact factor: 3.806

4.  Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.

Authors:  J Jankovic; J Orman
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

5.  Prevalence of the rabbit syndrome.

Authors:  R Yassa; S Lal
Journal:  Am J Psychiatry       Date:  1986-05       Impact factor: 18.112

6.  Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome?

Authors:  E Melamed; A Achiron; A Shapira; S Davidovicz
Journal:  Clin Neuropharmacol       Date:  1991-06       Impact factor: 1.592

7.  Drug-induced parkinsonism: a growing list.

Authors:  J F Martí Massó; N Carrera; M Urtasun
Journal:  Mov Disord       Date:  1993       Impact factor: 10.338

Review 8.  Drug-induced movement disorders.

Authors:  O S Gershanik
Journal:  Curr Opin Neurol Neurosurg       Date:  1993-06

9.  Drug-induced parkinsonism in the elderly.

Authors:  P J Stephen; J Williamson
Journal:  Lancet       Date:  1984-11-10       Impact factor: 79.321

10.  Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine.

Authors:  C Chouza; A Scaramelli; J L Caamaño; O De Medina; R Aljanati; S Romero
Journal:  Lancet       Date:  1986-06-07       Impact factor: 79.321

View more
  8 in total

Review 1.  Behavioural problems associated with dementia: the role of newer antipsychotics.

Authors:  G Stoppe; C A Brandt; J H Staedt
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

2.  Case files of the University of California San Francisco Medical Toxicology Fellowship: lamotrigine toxicity.

Authors:  Michelle Fleurat; Craig Smollin
Journal:  J Med Toxicol       Date:  2012-03

Review 3.  A comparative review of the adverse effects of calcium antagonists.

Authors:  H T Dougall; J McLay
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

4.  Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice.

Authors:  H Matsuo; A Matsui; R Nasu; H Takanaga; N Inoue; F Hattori; H Ohtani; Y Sawada
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

Review 5.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 6.  Treatment of schizophrenia and delusional disorder in the elderly.

Authors:  J H Eastham; D V Jeste
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

7.  Drug-induced parkinsonism.

Authors:  Hae-Won Shin; Sun Ju Chung
Journal:  J Clin Neurol       Date:  2012-03-31       Impact factor: 3.077

Review 8.  Experimental treatment of antipsychotic-induced movement disorders.

Authors:  Erum Shireen
Journal:  J Exp Pharmacol       Date:  2016-08-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.